$HIMS (-4,2 %)
$NOVO B (-3,08 %)

According to documents filed with the Canadian Patent Database, Novo held a patent for semaglutide, but the last time the company paid the annual maintenance fee was in 2018.

Novo Nordisk's lawyers requested a refund of the 2017 maintenance fee of 250 Canadian dollars (about 185 US dollars) because the company wanted more time to decide whether it wanted to pay the fee, according to letters attached to the documents.

Two years later, the office sent a letter stating that the fee - which had grown to a total of 450 Canadian dollars with a late payment surcharge - had not been received on time.

Novo Nordisk had a grace period of one year to make up the payment, but never did. The patent therefore expired in Canada. It expired in 2020 because the payment was not made, but does not officially expire until January.

The Canadian authorities confirmed in their correspondence: "Once a patent has lapsed, it cannot be revived."

"Making affordable, holistic obesity treatments accessible has the potential to strengthen the local healthcare system and enable millions of Canadians to lead healthier, more fulfilling lives," said David Meinertz, Managing Director of the International Obesity and Healthcare Business Unit.

Source: Hims & Hers offers generic semaglutide as Novo Nordisk patent lapses

Fun FactDavid Meinertz ex Zava CEO, is now responsible for global expansion

I've been wanting to get in for a while, but always had doubts. I've read a few positive things about Novo Nordisk over the last few days and have finally got in. I intend to hold the share for the long term. And I'm also hoping for a decent dividend yield in the future with the increase this year and hopefully more when the share goes up again.

I finally have Novo Nordisk in my portfolio🚀

$NOVO B (-3,08 %) has submitted a new, higher dose (7.2 mg) of its weight loss drug Wegovy® to the EMA.

In studies: 21 % average weight loss - a third of participants even lost 25 % or more. 🤯

And that with continued good tolerability. For me: a strong signal!

Why is this exciting?

✅ The GLP-1 market is booming, but Novo is showing that they are not only delivering, but also developing.

✅ New dose = new target group: people who couldn't lose enough weight with the 2.4 mg version.

✅ In the long term, it's not just about weight, but also about diabetes, heart, liver and co.

✅ And yes: Europe is a big market - with growing political pressure to finally take obesity seriously.

📈 Will the course take off immediately? Perhaps not spectacularly - but the path is right. I'm staying invested (for the long term). ✌🏻

I recently joined and have built up a little bit. I hope to build up something in the long term 😅 We'll see over the next few years

$TSLA (+1,03 %)
$NVDA (+0,68 %)
$NOVO B (-3,08 %)
$1211 (+0,29 %)
$MSFT (+0,41 %)
$NKE (-2,6 %)
$PATH (-4,34 %)

Before I head off to a garden party in 2 hours and stop writing for a while, I would like to share a few interesting thoughts on $NOVO B (-3,08 %) that I have just heard in a podcast (buy the Dip) and which have at least changed my way of thinking about the company from a trading perspective.

One of the 3 protagonists of the podcast has $NOVO B (-3,08 %) as a dividend stock in his long-term portfolio. He believes that the share will bring him a conservative annual return of 11-13% in the long term through a combination of price appreciation and dividends. So far, he has probably held it since 2017, this has worked out at 140%.

What do you generally think of such an approach? It comes very close to my original approach towards dividend stocks, except that I $NOVO B (-3,08 %) would not have put it in this category before.

$NOVO B (-3,08 %)
$LLY (+0,37 %)

$NOVO B (-3,08 %) reached its ATH almost exactly one year ago. Since then, the shares have fallen by over 50%. What do you think, will $LLY (+0,37 %) Novo Nordisk from the market or can you keep up?